Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Sold by Nuveen Asset Management LLC

Nuveen Asset Management LLC decreased its position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 17.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 414,104 shares of the biopharmaceutical company's stock after selling 88,468 shares during the quarter. Nuveen Asset Management LLC owned approximately 0.26% of Ocular Therapeutix worth $3,536,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in OCUL. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of Ocular Therapeutix by 22.0% during the 4th quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 270,422 shares of the biopharmaceutical company's stock worth $2,309,000 after purchasing an additional 48,763 shares during the last quarter. Millennium Management LLC purchased a new stake in shares of Ocular Therapeutix during the 4th quarter worth $3,819,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Ocular Therapeutix by 3.3% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 88,463 shares of the biopharmaceutical company's stock worth $755,000 after purchasing an additional 2,853 shares during the last quarter. Graham Capital Management L.P. purchased a new stake in shares of Ocular Therapeutix during the 4th quarter worth $321,000. Finally, D. E. Shaw & Co. Inc. purchased a new stake in shares of Ocular Therapeutix during the 4th quarter worth $268,000. Institutional investors own 59.21% of the company's stock.

Insider Buying and Selling at Ocular Therapeutix

In other news, Director Richard L. Md Lindstrom bought 10,000 shares of the firm's stock in a transaction dated Thursday, May 8th. The shares were acquired at an average price of $6.96 per share, for a total transaction of $69,600.00. Following the completion of the transaction, the director now directly owns 172,704 shares in the company, valued at $1,202,019.84. The trade was a 6.15% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Pravin Dugel sold 21,219 shares of Ocular Therapeutix stock in a transaction that occurred on Friday, May 23rd. The stock was sold at an average price of $7.18, for a total value of $152,352.42. Following the transaction, the insider now owns 3,499,099 shares in the company, valued at approximately $25,123,530.82. The trade was a 0.60% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 29,079 shares of company stock valued at $208,739. Company insiders own 2.30% of the company's stock.

Ocular Therapeutix Stock Performance

Shares of OCUL stock traded up $0.08 during mid-day trading on Thursday, reaching $8.46. The stock had a trading volume of 1,923,440 shares, compared to its average volume of 1,405,641. The business's fifty day moving average is $7.43 and its 200-day moving average is $7.90. The company has a current ratio of 13.01, a quick ratio of 12.94 and a debt-to-equity ratio of 0.19. The firm has a market cap of $1.35 billion, a price-to-earnings ratio of -6.41 and a beta of 1.51. Ocular Therapeutix, Inc. has a 1-year low of $4.79 and a 1-year high of $11.78.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last announced its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.05). The firm had revenue of $17.08 million during the quarter, compared to analyst estimates of $16.89 million. Ocular Therapeutix had a negative net margin of 283.74% and a negative return on equity of 45.18%. On average, research analysts forecast that Ocular Therapeutix, Inc. will post -0.98 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the company. William Blair assumed coverage on Ocular Therapeutix in a research note on Tuesday, April 8th. They issued an "outperform" rating for the company. HC Wainwright reiterated a "buy" rating and issued a $15.00 price target on shares of Ocular Therapeutix in a research note on Thursday, May 29th. JMP Securities set a $19.00 price target on Ocular Therapeutix in a research note on Tuesday, March 4th. Royal Bank of Canada assumed coverage on Ocular Therapeutix in a research note on Tuesday, March 18th. They issued an "outperform" rating and a $17.00 price target for the company. Finally, Needham & Company LLC decreased their price target on Ocular Therapeutix from $15.00 to $14.00 and set a "buy" rating for the company in a research note on Tuesday, May 6th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $16.25.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.